1887
Rapid communication Open Access
Like 0

Abstract

We investigated an outbreak of SARS-CoV-2 variant BA.2.86 in an East of England care home. We identified 45 infections (33 residents, 12 staff), among 38 residents and 66 staff. Twenty-nine of 43 PCR swabs were sequenced, all of which were variant BA.2.86. The attack rate among residents was 87%, 19 were symptomatic, and one was hospitalised. Twenty-four days after the outbreak started, no cases were still unwell. Among the 33 resident cases, 29 had been vaccinated 4 months earlier.

Loading

Article metrics loading...

/content/10.2807/1560-7917.ES.2023.28.39.2300489
2023-09-28
2024-02-22
http://instance.metastore.ingenta.com/content/10.2807/1560-7917.ES.2023.28.39.2300489
Loading
Loading full text...

Full text loading...

/deliver/fulltext/eurosurveillance/28/39/eurosurv-28-39-2.html?itemId=/content/10.2807/1560-7917.ES.2023.28.39.2300489&mimeType=html&fmt=ahah

References

  1. UK Health Security Agency (UKHSA). Risk assessment for SARS-CoV-2 variant V-23AUG-01 (BA.2.86) 2023. Updated 1 September 2023. London: UKHSA; 2023. Available from: https://www.gov.uk/government/publications/investigation-of-sars-cov-2-variants-of-concern-variant-risk-assessments/risk-assessment-for-sars-cov-2-variant-v-23aug-01-or-ba286
  2. UK Health Security Agency (UKHSA). Situational assessment for SARS-CoV-2 variant V-23AUG-01 (BA.2.86) 2023. Updated 1 September 2023. London: UKHSA; 2023. Available from: https://www.gov.uk/government/publications/investigation-of-sars-cov-2-variants-of-concern-variant-risk-assessments/situational-assessment-for-sars-cov-2-variant-v-23aug-01-ba286
  3. Rasmussen M, Møller FT, Gunalan V, Baig S, Bennedbæk M, Christiansen LE, et al. First cases of SARS-CoV-2 BA.2.86 in Denmark, 2023. Euro Surveill. 2023;28(36):2300460.  https://doi.org/10.2807/1560-7917.ES.2023.28.36.2300460  PMID: 37676147 
  4. 2nd-Generation BA.2 Saltation Lineage, >30 spike mutations (3 seq, 2 countries, Aug 14) #2183. Github; 2023. Available from: https://github.com/cov-lineages/pango-designation/issues/2183
  5. UK Health Security Agency (UKHSA). COVID-19 supplement to the infection prevention and control resource for adult social care. Updated 25 August 2023. London: UKHSA; 2023. Available from: https://www.gov.uk/government/publications/infection-prevention-and-control-in-adult-social-care-covid-19-supplement/covid-19-supplement-to-the-infection-prevention-and-control-resource-for-adult-social-care
  6. Tessier E, Edelstein M, Tsang C, Kirsebom F, Gower C, Campbell CNJ, et al. Monitoring the COVID-19 immunisation programme through a national immunisation Management system - England’s experience. Int J Med Inform. 2023;170:104974.  https://doi.org/10.1016/j.ijmedinf.2022.104974  PMID: 36577202 
  7. UK Health Security Agency (UKHSA). A guide to the COVID-19 spring booster 2023. Updated 26 April 2023. London: UKHSA; 2023. Available from: https://www.gov.uk/government/publications/covid-19-vaccination-spring-booster-resources/a-guide-to-the-covid-19-spring-booster-2023
  8. ARTICnetwork. SARS-CoV-2 Updates [07/09/2023]. Available from: https://artic.network/ncov-2019
  9. O’Toole Á, Scher E, Underwood A, Jackson B, Hill V, McCrone JT, et al. Assignment of epidemiological lineages in an emerging pandemic using the pangolin tool. Virus Evol. 2021;7(2):veab064.  https://doi.org/10.1093/ve/veab064  PMID: 34527285 
  10. Khare S, Gurry C, Freitas L, Schultz MB, Bach G, Diallo A, et al. GISAID’s Role in Pandemic Response. China CDC Wkly. 2021;3(49):1049-51.  https://doi.org/10.46234/ccdcw2021.255  PMID: 34934514 
  11. UK Health Security Agency (UKHSA). SARS-CoV-2 variant surveillance and assessment: technical briefing 53. Updated 14 September 2023. London: UKHSA; 2023. Available from: https://www.gov.uk/government/publications/investigation-of-sars-cov-2-variants-technical-briefings/sars-cov-2-variant-surveillance-and-assessment-technical-briefing-53
  12. UK Health Security Agency (UKHSA). Evaluation of lateral flow device performance within the National Testing Programme. Date of reporting period: 8 November 2020 to 21 March 2022. London: UKHSA; 2023. Available from: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1121707/LFD_Performance_within_the_NTP_Report.pdf
  13. Choudhry S, Rowland TAJ, McClelland K, Renz E, Iyanger N, Chow JY, et al. Protection from infection and reinfection due to the Omicron BA.1 variant in care homes. Front Immunol. 2023;14. (Forthcoming). "https://doi.org/10.3389/fimmu.2023.1186134" https://doi.org/10.3389/fimmu.2023.1186134 
  14. Williams SV, Vusirikala A, Ladhani SN, Fernandez Ruiz De Olano E, Iyanger N, Aiano F, et al. An outbreak caused by the SARS-CoV-2 Delta (B.1.617.2) variant in a care home after partial vaccination with a single dose of the COVID-19 vaccine Vaxzevria, London, England, April 2021. Euro Surveill. 2021;26(27):2100626.  https://doi.org/10.2807/1560-7917.ES.2021.26.27.2100626  PMID: 34240699 
  15. Hall VJ, Insalata F, Foulkes S, Kirwan P, Sparkes D, Atti A, et al. Effectiveness of BNT162b2 mRNA vaccine third doses and previous infection in protecting against SARS-CoV-2 infections during the Delta and Omicron variant waves; the UK SIREN cohort study September 2021 to February 2022. medRxiv. 2023:2023.05.22.23290197 . https://doi.org/10.1101/2023.05.22.23290197 
  16. Andrews N, Stowe J, Kirsebom F, Toffa S, Rickeard T, Gallagher E, et al. Covid-19 vaccine effectiveness against the Omicron (B.1.1.529) variant. N Engl J Med. 2022;386(16):1532-46.  https://doi.org/10.1056/NEJMoa2119451  PMID: 35249272 
  17. Stowe J, Andrews N, Kirsebom F, Ramsay M, Bernal JL. Effectiveness of COVID-19 vaccines against Omicron and Delta hospitalisation, a test negative case-control study. Nat Commun. 2022;13(1):5736.  https://doi.org/10.1038/s41467-022-33378-7  PMID: 36180428 
/content/10.2807/1560-7917.ES.2023.28.39.2300489
Loading

Data & Media loading...

Supplementary data

Submit comment
Close
Comment moderation successfully completed
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error